亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Iodine-125 brachytherapy triggers immunogenic cell death and potentiates anti-PD-L1 immunotherapy in bone metastatic triple-negative breast cancer

医学 免疫原性细胞死亡 免疫疗法 免疫系统 癌症研究 骨转移 转移 乳腺癌 转移性乳腺癌 肿瘤微环境 免疫检查点 肿瘤科 近距离放射治疗 癌症 内科学 骨髓 癌症免疫疗法 癌细胞 体内 背向效应 T细胞 免疫 程序性细胞死亡 免疫学 细胞 疫苗疗法
作者
Min Li,Zhenzhen Cui,Jiaxin Yang,Qiyu Sun,Yanbo Hu,Juan Shen,Zhihao Li,Xiaoyang Han,Yi Wang,Jiageng Tang,Hengsong Yu,Xiaowen Ma,Jing Wang
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:17: 1761538-1761538 被引量:2
标识
DOI:10.3389/fimmu.2026.1761538
摘要

Introduction Triple-negative breast cancer (TNBC) with bone metastasis is challenging to treat due to an immunosuppressive microenvironment and the limited, transient immune activation from conventional external beam radiotherapy. Inducing immunogenic cell death (ICD) offers a strategy to remodel this environment, but its systemic effects remain to be validated. Here, we investigate iodine-125 ( 125 I) brachytherapy as a method to induce sustained ICD and activate systemic antitumor immunity in TNBC bone metastasis using transcriptomic analysis, a dual-tumor model, and CALR-targeted molecular imaging. Methods A dual-tumor model of 4T1 mouse breast cancer with tibial bone metastasis and distal subcutaneous implantation was established. The therapeutic efficacy of ¹²⁵ I seeds at different doses (0.3-0.8 mCi), alone or in combination with anti–PD-L1 antibody, was systematically assessed. ICD biomarkers (CALR, HMGB1) and immune cell infiltration were analyzed using Western blot, qRT-PCR, immunohistochemistry, and flow cytometry. Transcriptome sequencing was performed to explore changes in ICD and related immune pathways. In vivo dynamic imaging of ICD was achieved using a CALR-targeting bimodal nanoprobe. Comparative analyses were conducted between 125 I brachytherapy and EBRT to assess differences in tumor control and immune activation. Treatment sequencing studies were performed to evaluate the optimal combination strategy. Results This study confirmed that 125 I seeds effectively induce sustained immunogenic cell death, significantly upregulating damage-associated molecular patterns (DAMPs) such as CALR and HMGB1. In the 4T1 bone metastasis model, local implantation of 125 I (0.3-0.8 mCi) inhibited tumor growth in a dose-dependent manner, with the 0.8 mCi group showing the best therapeutic effect and no significant toxicity. Mechanistically, 125 I promoted CD8α⁺T cell infiltration, activated ICD-related pathways, and triggered systemic antitumor immunity, as demonstrated by inhibition of distant tumor growth in the bilateral tumor system. Compared with EBRT, 125I brachytherapy achieved superior local control and more robust immune activation. Using a CALR-targeting nanoprobe, dynamic in vivo imaging of ICD was successfully achieved. Treatment sequencing studies revealed that initiating with 125 I brachytherapy followed by combination therapy with PD-L1 antibody and Abraxane resulted in the most favorable outcome, confirming this “ 125 I-first” approach as an effective immune priming strategy. Discussion This study demonstrates that 125 I brachytherapy overcomes the limitations of conventional radiotherapy by inducing sustained immunogenic cell death, remodeling the tumor immune microenvironment, and activating systemic antitumor immunity. 125 I seeds not only inhibit the growth of TNBC bone metastases and distal tumors but also significantly enhance the infiltration of CD8α ⁺ T cells into tumor sites. Notably, the sequential regimen of 125 I brachytherapy followed by PD-L1 antibody and Abraxane shows significant synergistic effects. These findings establish 125 I brachytherapy as a superior immune-priming modality and provide a mechanistic rationale for integrating low-dose-rate brachytherapy with immunotherapy to overcome resistance in bone-metastatic TNBC, offering strong potential for clinical translation., iodine-125 seeds, triple-negative breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
风趣含双发布了新的文献求助10
1秒前
体贴的小霜完成签到,获得积分10
4秒前
7秒前
天天快乐的应助被lmn采纳,获得10
7秒前
ZhengGangan完成签到,获得积分10
9秒前
rtx00发布了新的文献求助10
12秒前
Jun的应助被黎涵采纳,获得10
17秒前
22秒前
李威萱发布了新的文献求助10
27秒前
32秒前
万能图书馆的应助被黎涵采纳,获得10
38秒前
42秒前
may发布了新的文献求助10
49秒前
曾经的盼望完成签到,获得积分10
51秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
57秒前
上官若男的应助被科研通管家采纳,获得10
58秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
58秒前
大模型的应助被科研通管家采纳,获得20
58秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
58秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
58秒前
CAOHOU的应助被虚心的灵寒采纳,获得10
1分钟前
1分钟前
1分钟前
务实玫瑰完成签到,获得积分10
1分钟前
点点凡尘完成签到,获得积分10
1分钟前
科研小白发布了新的文献求助10
1分钟前
汉堡包的应助被科研小白采纳,获得10
1分钟前
可爱的函函的应助被董翰采纳,获得10
1分钟前
CAOHOU的应助被徐锦怡采纳,获得10
1分钟前
斯文败类的应助被LBB采纳,获得10
1分钟前
1分钟前
1分钟前
饱满飞绿完成签到,获得积分10
1分钟前
lmn发布了新的文献求助10
1分钟前
1分钟前
molihuakai的应助被涂豆泥采纳,获得10
1分钟前
小叶子完成签到 ,获得积分10
1分钟前
1分钟前
董翰发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172945
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21779948
捐赠科研通 7764804
什么是DOI,文献DOI怎么找? 3431480
关于科研通互助平台的介绍 2555510
邀请新用户注册赠送积分活动 2476564